Dow Today: Pfizer (PFE) Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

The Dow Jones Industrial Average ( ^DJI) is trading down 157.0 points (-1.1%) at 14,708 as of Monday, Apr 15, 2013, 12:35 p.m. ET. During this time, 289.3 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 600 million. The NYSE advances/declines ratio sits at 426 issues advancing vs. 2,527 declining with 106 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader Dow index with a six-cent decline (-0.2%) bringing the stock to $30.61. This single loss is lowering the Dow Jones Industrial Average by 0.45 points or roughly accounting for 0.3% of the Dow's overall loss. Volume for Pfizer currently sits at 19.9 million shares traded vs. an average daily trading volume of 32.1 million shares.

Pfizer has a market cap of $220.17 billion and is part of the health care sector and drugs industry. Shares are up 22.3% year to date as of Friday's close. The stock's dividend yield sits at 3.1%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company has a P/E ratio of 24.3, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.